The global acne treatment market size was estimated to be USD 11.06 billion in 2023 and is expected to reach at USD 19.91 billion by 2034 with a CAGR of 5.49% during the forecast period 2024-2034. Increasing incidence of the condition among teenagers & adults, growing prevalence of skin conditions, surge in the number of patients seeking treatment, rising introduction of diverse products including retinoids, isotretinoids, & antibiotics in both oral and topical forms, a heightened awareness about acne products & the various treatment options available, increasing demand for effective drugs to treat this condition, and growing introduction of innovative drugs for acne treatment are some of the key factors boosting the market growth.
Growing introduction of innovative drugs for acne treatment is predicted to boost the market growth during the forecast period. Acne is a skin condition resulting from the blockage of hair follicles by a combination of dead skin cells and oil. Although it predominantly occurs in teenagers, individuals of all age groups can be affected. Commonly prescribed medications include antibiotics, retinoids, and retinoid-like drugs. The rising incidence of skin disorders is a key factor contributing to the global demand for acne treatment products in the projected period. For instance, in June 2022, Zydus Lifesciences has obtained approval from the U.S. FDA to market a generic Adapalene and Benzoyl Peroxide topical gel in the United States. This medication is intended for the treatment of acne.
By product, antibiotics was the highest revenue-grossing segment in the global acne treatment market in 2023 owing to increasing endorsements of antibiotics for treating acne, coupled with their effectiveness in managing exudate. Additionally, retinoids is predicted to grow at fastest CAGR during the forecast period owing to the rising incidence of moderate to severe acne, a growing request for retinoids, and increasing mergers & acquisitions within market players. For instance, in January 2022, GALDERMA has announced the receipt of antitrust clearance from U.S. authorities following the successful completion of the acquisition of ALASTIN Skincare, Inc. This acquisition is aimed at advancing the development of innovative and clinically-tested skincare products for dispensation by physicians.
By route of administration, topical was the highest revenue-grossing segment in the global acne treatment market in 2023 owing to the rising number of companies producing topical solutions for treating acne is linked to the patient demographic affected by the condition. This demographic is particularly interested in topical solutions due to their widespread availability and convenience. For instance, in March 2022, Galderma has launched its revolutionary skincare cream, Twyneo, designed to address moderate to severe facial acne. During the American Academy of Dermatology (AAD) Annual Meeting, the product was first launched to the U.S. market. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to an increase in the condition's prevalence and the growing number of product launches.
By age group, 18 to 44 years was the highest revenue-grossing segment in the global acne treatment market in 2023 owing to the rise in the number of patients within this specific age group and rising introduction of nre products. For instance, in September 2022, La Roche-Posay has unveiled the Effaclar Salicylic Acid Acne Treatment Serum, specifically designed for addressing adult acne. Additionally, 10 to 17 years is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of acne vulgaris among the specified teenage demographic.
By distribution channel, retail & online pharmacies seg was the highest revenue-grossing segment in the global acne treatment market in 2023 owing to the rise in the quantity of online portals and websites marketing products for acne treatment, including platforms like Walmart, Amazon, and various others, reflects the increasing demand for over-the-counter (OTC) drugs, and growing collaborations within market players. For instance, in July 2022, Sun Pharmaceutical Industries has broadened its partnership with Cassiopea to provide WINLEVI in Australia, Japan, New Zealand, and three additional countries. Additionally, hospital pharmacies is predicted to grow at fastest CAGR during the forecast period owing to a rise in hospital visits for the treatment of this illness.
North America region is anticipated for the highest revenue share during the forecast period owing to the escalating occurrence of acne, heightened beauty-related concerns among the population, a surge in the number of patients, an increasing awareness of advanced treatment options, and growing the introduction of novel drugs. For instance, in December 2022, Bausch Health Companies Inc. has declared the accessibility of ARAZLO, a novel treatment for acne vulgaris, for patients through the provincial public drug plans in Canada. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing awareness among the population regarding various drugs, an elevated prevalence of moderate to severe acne, substantial investment in research and development by major companies for drugs used in dermatology treatment, an increased uptake of advanced treatment products, and rising launch of new products. For instance, in July 2022, Glenmark Pharmaceuticals has introduced a new acne medication, MINYM gel, in India. This marks the country's initial topical Minocycline 4% Gel designed for the treatment of acne.
Growing introduction of innovative drugs for acne treatment is predicted to boost the market growth during the forecast period. Acne is a skin condition resulting from the blockage of hair follicles by a combination of dead skin cells and oil. Although it predominantly occurs in teenagers, individuals of all age groups can be affected. Commonly prescribed medications include antibiotics, retinoids, and retinoid-like drugs. The rising incidence of skin disorders is a key factor contributing to the global demand for acne treatment products in the projected period. For instance, in June 2022, Zydus Lifesciences has obtained approval from the U.S. FDA to market a generic Adapalene and Benzoyl Peroxide topical gel in the United States. This medication is intended for the treatment of acne.
By product, antibiotics was the highest revenue-grossing segment in the global acne treatment market in 2023 owing to increasing endorsements of antibiotics for treating acne, coupled with their effectiveness in managing exudate. Additionally, retinoids is predicted to grow at fastest CAGR during the forecast period owing to the rising incidence of moderate to severe acne, a growing request for retinoids, and increasing mergers & acquisitions within market players. For instance, in January 2022, GALDERMA has announced the receipt of antitrust clearance from U.S. authorities following the successful completion of the acquisition of ALASTIN Skincare, Inc. This acquisition is aimed at advancing the development of innovative and clinically-tested skincare products for dispensation by physicians.
By route of administration, topical was the highest revenue-grossing segment in the global acne treatment market in 2023 owing to the rising number of companies producing topical solutions for treating acne is linked to the patient demographic affected by the condition. This demographic is particularly interested in topical solutions due to their widespread availability and convenience. For instance, in March 2022, Galderma has launched its revolutionary skincare cream, Twyneo, designed to address moderate to severe facial acne. During the American Academy of Dermatology (AAD) Annual Meeting, the product was first launched to the U.S. market. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to an increase in the condition's prevalence and the growing number of product launches.
By age group, 18 to 44 years was the highest revenue-grossing segment in the global acne treatment market in 2023 owing to the rise in the number of patients within this specific age group and rising introduction of nre products. For instance, in September 2022, La Roche-Posay has unveiled the Effaclar Salicylic Acid Acne Treatment Serum, specifically designed for addressing adult acne. Additionally, 10 to 17 years is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of acne vulgaris among the specified teenage demographic.
By distribution channel, retail & online pharmacies seg was the highest revenue-grossing segment in the global acne treatment market in 2023 owing to the rise in the quantity of online portals and websites marketing products for acne treatment, including platforms like Walmart, Amazon, and various others, reflects the increasing demand for over-the-counter (OTC) drugs, and growing collaborations within market players. For instance, in July 2022, Sun Pharmaceutical Industries has broadened its partnership with Cassiopea to provide WINLEVI in Australia, Japan, New Zealand, and three additional countries. Additionally, hospital pharmacies is predicted to grow at fastest CAGR during the forecast period owing to a rise in hospital visits for the treatment of this illness.
North America region is anticipated for the highest revenue share during the forecast period owing to the escalating occurrence of acne, heightened beauty-related concerns among the population, a surge in the number of patients, an increasing awareness of advanced treatment options, and growing the introduction of novel drugs. For instance, in December 2022, Bausch Health Companies Inc. has declared the accessibility of ARAZLO, a novel treatment for acne vulgaris, for patients through the provincial public drug plans in Canada. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing awareness among the population regarding various drugs, an elevated prevalence of moderate to severe acne, substantial investment in research and development by major companies for drugs used in dermatology treatment, an increased uptake of advanced treatment products, and rising launch of new products. For instance, in July 2022, Glenmark Pharmaceuticals has introduced a new acne medication, MINYM gel, in India. This marks the country's initial topical Minocycline 4% Gel designed for the treatment of acne.
Segmentation: Acne Treatment Market Report 2023 - 2034
Acne Treatment Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Retinoids
- Antibiotics
- Isotretinoin
- Others
Acne Treatment Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Oral
- Topical
Acne Treatment Market Analysis & Forecast by Age Group 2023 - 2034 (Revenue USD Bn)
- 10 To 17 Years
- 18 To 44 Years
- 45 To 64 Years
- 65 Years & Above
Acne Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail & Online Pharmacies
Acne Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Acne Treatment Market: Product Estimates & Trend Analysis
8. Acne Treatment Market: Route of Administration Estimates & Trend Analysis
9. Acne Treatment Market: Age Group Estimates & Trend Analysis
10. Acne Treatment Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Acne Treatment Market
13. Europe Global Acne Treatment Market
14. Asia Pacific Global Acne Treatment Market
15. Latin America Global Acne Treatment Market
16. MEA Global Acne Treatment Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- The BeautyHealth Company
- Skin Medica
- Sente
- Bausch Health Companies Inc
- Colorescience
- Skin Better Science
- Jan Marini Skin Research
- Obaji
- Revision Skincare
- Perricone MD
- Glenmark Pharmaceuticals
- Glow Biotics LLC
- PHYTOMER
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 11.06 Billion |
| Forecasted Market Value ( USD | $ 19.91 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
